reAlpha Enhances Mortgage Operations with AI-Powered Loan Officer Assistant Prism Labs Announces First-of-its-kind Mobile Bodymapping Technology with Integration into the Tempo Fitness Platform
LOS ANGELES–(BUSINESS WIRE)–Prism Labs, a startup democratizing access to 3D bodymapping technology, is excited to…
Memphis.dev Disrupts Event Streaming with Introduction of Memphis Cloud to Accelerate Development of Real-time Applications in Multi-cloud Environments
Intelligent open source platform enables developers to get started with real-time data in less than…
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) — June 28, 2023 – Sirona Biochem…
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) — June 28, 2023 – Sirona Biochem…
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A…
UPDATE — Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase…
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A…
Reflect Scientific Inc Receives Order for B-90 Plasma Freezer, Continues to Expand Clientele
OREM, Utah, June 28, 2023 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (OTCQB: RSCF), a leading…
UPDATE — Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase…
Reflect Scientific Inc Receives Order for B-90 Plasma Freezer, Continues to Expand Clientele
OREM, Utah, June 28, 2023 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (OTCQB: RSCF), a leading…
Ambrx Announces Closing of $75 Million Market Priced Registered Offering
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (or the…
Ambrx Announces Closing of $75 Million Market Priced Registered Offering
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (or the…
Cerevance Announces Presentation at the XVI European Meeting on Glial Cells in Health and Disease
BOSTON, June 28, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
Cerevance Announces Presentation at the XVI European Meeting on Glial Cells in Health and Disease
BOSTON, June 28, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the…
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the…
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival…
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival…